Phase 1/2 Trial of Total Marrow and Lymph Node Irradiation to Augment Reduced-intensity Transplantation for Advanced Hematologic Malignancies

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2010 Sep 30

PMID 20876852

Citations 38

Authors

Joseph Rosenthal

Jeffrey Wong

Anthony Stein

Dajun Qian

Debbie Hitt

Hossameldin Naeem

Andrew Dagis

Sandra H Thomas

Stephen Forman

Affiliations

Soon will be listed here.

Abstract

This phase 1/2 study assessed the augmentation of reduced-intensity conditioning (RIC) with total marrow and lymph node irradiation (TMLI), for peripheral blood stem cell transplantation, in patients with advanced hematologic disease. The regimen consisted of fludarabine 25 mg/m(2) per day for 5 days, melphalan 140 mg/m(2) for one day, and TMLI radiation at 150 cGy/fraction in 8 fractions over 4 days. Eligible patients were over 50 years old and/or had compromised organ function. Median age of the 33 evaluable patients was 55.2 years. Eighteen events of nonhematologic grade III or higher toxicities occurred in 9 patients. Day 30 and day 100 mortalities were 3% and 15%, respectively. Patients achieved myeloid and platelet engraftment at a median of 14 days after transplantation. Long-term toxicities occurred in 2 patients: hypokalemia and tremor, both grade III, on days 370 and 361 after transplantation. Fourteen patients died, 7 of relapse-related causes and 7 of non-relapse-related causes. With a median follow-up for living patients of 14.7 months, 1-year overall survival, event-free survival, and non-relapse-related mortality were 75%, 65%, and 19%, respectively. Addition of TMLI to RIC is feasible and safe and could be offered to patients with advanced hematologic malignancies who might not otherwise be candidates for RIC.

Citing Articles

Novel conditioning and prophylaxis regimens for relapse prevention.

Mancusi A, Ruggeri L, Pierini A Hematology Am Soc Hematol Educ Program. 2024; 2024(1):627-634.

PMID: 39644026 PMC: 11665651. DOI: 10.1182/hematology.2024000590.

Maintain Efficacy and Spare Toxicity: Traditional and New Radiation-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation.

Dogliotti I, Levis M, Martin A, Bartoncini S, Felicetti F, Cavallin C Cancers (Basel). 2024; 16(5).

PMID: 38473227 PMC: 10931277. DOI: 10.3390/cancers16050865.

How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia.

Velardi A, Mancusi A, Ruggeri L, Pierini A Bone Marrow Transplant. 2024; 59(3):301-305.

PMID: 38212671 DOI: 10.1038/s41409-024-02199-1.

Total marrow irradiation in hematopoietic stem cell transplantation for hematologic malignancies.

Kerbauy M, Arcuri L, Favareto S, de Rezende A, Hamerschlak N Front Med (Lausanne). 2023; 10:1155954.

PMID: 37153098 PMC: 10157478. DOI: 10.3389/fmed.2023.1155954.

Internal Guidelines for Reducing Lymph Node Contour Variability in Total Marrow and Lymph Node Irradiation.

Dei D, Lambri N, Stefanini S, Vernier V, Brioso R, Crespi L Cancers (Basel). 2023; 15(5).

PMID: 36900326 PMC: 10000500. DOI: 10.3390/cancers15051536.

References

Giralt S, Logan B, Rizzo D, Zhang M, Ballen K, Emmanouilides C . Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant. 2007; 13(7):844-52. DOI: 10.1016/j.bbmt.2007.03.011. View

Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M . Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica. 2007; 92(5):627-34. DOI: 10.3324/haematol.10924. View

Berger C, Le-Gallo B, Donadieu J, Richard O, Devergie A, Galambrun C . Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplant. 2005; 35(10):991-5. DOI: 10.1038/sj.bmt.1704945. View

Boulad F, Bromley M, Black P, Heller G, Sarafoglou K, Gillio A . Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant. 1995; 15(1):71-6. View

Ritchie D, Morton J, Szer J, Roberts A, Durrant S, Shuttleworth P . Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2003; 9(7):435-42. DOI: 10.1016/s1083-8791(03)00128-9. View

Bradley J, Reft C, Goldman S, Rubin C, Nachman J, Larson R . High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: treatment technique and related complications. Int J Radiat Oncol Biol Phys. 1998; 40(2):391-6. DOI: 10.1016/s0360-3016(97)00578-6. View

Michel G, Socie G, Gebhard F, Bernaudin F, Thuret I, Vannier J . Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de.... J Clin Oncol. 1997; 15(6):2238-46. DOI: 10.1200/JCO.1997.15.6.2238. View

Balog J, Mackie T, Pearson D, Hui S, Paliwal B, Jeraj R . Benchmarking beam alignment for a clinical helical tomotherapy device. Med Phys. 2003; 30(6):1118-27. DOI: 10.1118/1.1576395. View

Blaise D, Vey N, Faucher C, Mohty M . Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2007; 92(4):533-41. DOI: 10.3324/haematol.10867. View

10.

Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P . Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002; 30(6):367-73. DOI: 10.1038/sj.bmt.1703652. View

11.

Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L . A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994; 83(9):2723-30. View

12.

Socie G, Curtis R, Deeg H, Sobocinski K, Filipovich A, Travis L . New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000; 18(2):348-57. DOI: 10.1200/JCO.2000.18.2.348. View

13.

de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C . Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004; 104(3):865-72. DOI: 10.1182/blood-2003-11-3750. View

14.

Kebriaei P, Detry M, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D . Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood. 2007; 110(9):3456-62. DOI: 10.1182/blood-2007-04-085969. View

15.

Wong J, Liu A, Schultheiss T, Popplewell L, Stein A, Rosenthal J . Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transplant. 2006; 12(3):306-15. DOI: 10.1016/j.bbmt.2005.10.026. View

16.

Clift R, Buckner C, Appelbaum F, Bearman S, Petersen F, Fisher L . Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990; 76(9):1867-71. View

17.

Petropoulos D, Worth L, Mullen C, Madden R, Mahajan A, Choroszy M . Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Bone Marrow Transplant. 2006; 37(5):463-7. DOI: 10.1038/sj.bmt.1705278. View

18.

BIGGS J, Horowitz M, Gale R, Ash R, Atkinson K, Helbig W . Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood. 1992; 80(4):1090-3. View

19.

Bearman S, Appelbaum F, Buckner C, Petersen F, Fisher L, Clift R . Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988; 6(10):1562-8. DOI: 10.1200/JCO.1988.6.10.1562. View

20.

Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F . Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the.... Blood. 2002; 99(3):731-5. DOI: 10.1182/blood.v99.3.731. View